Direkte Kosten der Parkinson-Behandlung

Ehret, R.; Balzer‐Geldsetzer, Monika; Reese, JP; Dodel, I.; Becker, E.; Christopher, Alicia; Friedrich, H.; Kraemer, S.; Lüer, W.; Müngersdorf, Martina; Puzich, R; Rohr, Axel; Schultes-Platzek, I; Siefjediers,; Tiel-Wilck, Klaus; Oertel, WH; Dodel, Richard

doi:10.1007/s00115-009-2671-y

Cited by 17 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compared to other chronic neurological diseases such as Parkinson’s disease, the predominance of medication cost becomes obvious (EUR 14,500 vs. 6,800 annually [42]). …”

Section: Discussionmentioning

confidence: 99%

Economic Burden in a German Cohort of Patients with Multiple Sclerosis

Reese

John²,

Wienemann³

et al. 2011

Eur Neurol

View full text Add to dashboard Cite

Aims: To estimate costs of multiple sclerosis (MS) in a German cohort according to severity of the disease and clinical symptoms. Methods: 144 patients were recruited from an MS outpatient clinic. Costs were calculated according to current German health-economic guidelines from the perspective of the social health insurance system. Patients were either interviewed or completed a questionnaire. Cost assessment covered a 3-month period. Health outcomes were: Expanded Disability Status Scale, MS Functional Composite, Functional Assessment of MS, fatigue, depression (Beck Depression Inventory II) and patients’ socioeconomic status. Multivariate linear regression identified independent cost predictors. Results: Total quarterly costs per patient were EUR 10,329 (95% CI 9,357–11,390). Direct costs were EUR 5,344 for the social health insurance system and EUR 140 for the patient. Drugs represented the major share of direct costs (and 35% of total costs); indirect costs accounted for 47% of total costs. Univariate and multivariate analyses identified age, disability, fatigue and depression as independent predictors for total, indirect or drug costs. Conclusion: MS represents a high economic burden, with direct costs exceeding indirect costs. To reduce costs, research should focus on prevention that slows down progression of MS. Rehabilitation and symptomatic treatment may have merits in decreasing indirect costs.

show abstract

“…Compared to other chronic neurological diseases such as Parkinson’s disease, the predominance of medication cost becomes obvious (EUR 14,500 vs. 6,800 annually [42]). …”

Section: Discussionmentioning

confidence: 99%

Economic Burden in a German Cohort of Patients with Multiple Sclerosis

Reese

John²,

Wienemann³

et al. 2011

Eur Neurol

View full text Add to dashboard Cite

show abstract

“…Die individuellen Krankheitskosten steigen mit Fortschreiten der Erkrankung [11,12]. Je nach Stadium der Krankheit betrugen die Kosten zwischen 443D und 791D pro Monat; dabei wurden 87% für Medikamente und ca.…”

Section: Folgen Für Die Gesellschaftunclassified

“…Je nach Stadium der Krankheit betrugen die Kosten zwischen 443D und 791D pro Monat; dabei wurden 87% für Medikamente und ca. 4% für Heilmittel ausgegeben [11]. Die Kosten für Medikamente sind bei Klienten mit Bewegungsstörungen (Dyskinesie) höher als bei Erkrankten ohne motorische Komplikationen [12].…”

Section: Folgen Für Die Gesellschaftunclassified

See 1 more Smart Citation

Potenzialanalyse zur physiotherapeutischen Laufbandtherapie bei Morbus Parkinson

Lohkamp

Braun

Wasner

et al. 2014

Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheit

View full text Add to dashboard Cite

“…More precisely, we identified only 4 studies from the early 1990s [6,7,8,9], which are methodologically heterogeneous, limited in its scope and detail and provide highly variable results [10]. Thus, it is difficult to estimate the disease burden caused by PD as well as to specify what proportion of the population is affected by different degrees of severity and the degree of met and unmet needs for diagnosis and treatment.…”

Section: Introductionmentioning

confidence: 99%

Prevalence, Duration and Severity of Parkinson's Disease in Germany: A Combined Meta-Analysis from Literature Data and Outpatient Samples

Enders¹,

Balzer‐Geldsetzer²,

Riedel³

et al. 2017

Eur Neurol

View full text Add to dashboard Cite

Background: Epidemiological data on the prevalence of Parkinson's disease (PD) in Germany are limited. The aims of this study were to estimate the age- and gender-specific prevalence of PD in Germany as well as the severity and illness duration. Summary: A systematic literature search was performed in 5 different databases. European studies were included if they reported age- and gender-specific numbers of prevalence rates of PD. Meta-analytic approaches were applied to derive age- and gender-specific pooled prevalence estimates. Data of 4 German outpatient samples were incorporated to calculate the proportion of patients with PD in Germany grouped by Hoehn and Yahr (HY) stages and disease duration. In the German population, 178,169 cases of PD were estimated (prevalence: 217.22/100,000). The estimated relative illness duration was 40% with less than 5 years, 31% with 5-9 years, and 29% with more than 9 years. The proportions for different HY stages were estimated at 13% (I), 30% (II), 35% (III), 17% (IV), and 4% (V), respectively. Key Message: We provide an up-to-date estimation of age- and gender-specific as well as severity-based prevalence figures for PD in Germany. Further community studies are needed to estimate population-based severity distributions and distributions of non-motor symptoms in PD.

show abstract

Direkte Kosten der Parkinson-Behandlung

Cited by 17 publications

References 15 publications

Economic Burden in a German Cohort of Patients with Multiple Sclerosis

Economic Burden in a German Cohort of Patients with Multiple Sclerosis

Potenzialanalyse zur physiotherapeutischen Laufbandtherapie bei Morbus Parkinson

Prevalence, Duration and Severity of Parkinson's Disease in Germany: A Combined Meta-Analysis from Literature Data and Outpatient Samples

Contact Info

Product

Resources

About